Diabetes mellitus (DM) is a risk factor for morbidity and mortality in patients with heart failure. The effect of DM on postleft ventricular assist device (LVAD) implantation outcomes is unclear. This study sought to investigate whether patients with DM had worse outcomes than patients without DM after LVAD implantation and whether LVAD support resulted in a better control of DM.
D
iabetes mellitus (DM) is a rising worldwide epidemic with ≈9.3% of the population in the United States has DM, and >1.4 million American individuals are diagnosed with DM annually. 1 Patients with DM are at a substantially increased risk of developing heart failure (HF), 2 and despite optimal medical therapy, many proceed to stage D HF that requires advanced therapies, such as left ventricular assist device (LVAD) support. Patients with HF and DM have a greater risk of adverse clinical outcomes, including recurrent hospitalization and death, as compared with those without DM. [3] [4] [5] However, there is little evidence to indicate that glycemic control reduces the incidence of adverse events in patients with advanced HF. Studies that have targeted glycosylated hemoglobin (HbA1c) among participants with DM and HF are inconsistent with some have found favorable cardiovascular outcomes 6 while others have paradoxically reported increased mortality with lower HbA1c target. 7, 8 Less is known about the impact of DM on outcomes of patients supported with continuous flow LVAD (CF-LVAD), and some small studies have shown inconsistent results. [9] [10] [11] The International Society for Heart and Lung Transplantation recommendation to consider the presence of DM and poor glycemic control or severe DM-associated end-organ damage as a relative contraindication for LVAD implantation is thus based on data generated from the general DM population with HF, as well as on limited data from studies on outcomes of small groups of patients with DM supported with LVAD (Class Iib; Level of Evidence C). 12 These studies have suggested increased mortality and ischemic stroke rate in patients with DM. More recently, a retrospective study has shown that DM was not associated with statistically significant differences in mortality or rates of major adverse events during CF-LVAD support. 11 However, this study was also limited by a relatively small number of events because of the inclusion of predominantly bridge to transplant (BTT) LVAD recipients and shorter duration of LVAD support.
In this study, we sought to investigate the effect of preoperative DM on mortality and major adverse events in patients after CF-LVAD implantation and determine whether LVAD support results in a favorable DM control, based on our institutional 9-year experience at Mayo Clinic.
METHODS

Data Source
Our study protocol was approved by the Institutional Review Board of Mayo Clinic College of Medicine. We identified all consecutive adult patients (age ≥18 Patients who required temporary left-sided mechanical circulatory support but did not proceed with durable support with LVAD, those who required biventricular assist device, or total artificial heart were excluded from the analysis.
Clinical and Demographic Data
Demographic, clinical, echocardiographic, LVAD, and laboratory data were obtained from the Mayo Clinic College of Medicine-collected clinical database. Anti-DM medications, including total dose of long-and short-acting insulin, fasting blood glucose levels, and HbA1c levels, were reviewed and recorded at the last visit before LVAD implantation, at the first and last outpatient visit after LVAD implantation. The estimated glomerular filtration rate was calculated by the Chronic Kidney Disease Epidemiology Collaboration equation.
WHAT IS NEW?
• Diabetes mellitus is common in patients with heart failure. The impact of diabetes mellitus and glycemic control on clinical outcomes among diabetic patients with advanced heart failure requiring left ventricular assist device (LVAD) support is unclear.
• The present study found that patients with diabetes mellitus have decreased survival rates and increased complications, including higher rates of device infection and pump thrombosis, as compared with patients without diabetes mellitus, regardless of glycemic control before LVAD implantation.
• LVAD support in the diabetic population results in a significant decrease in hemoglobin A1C and in requirements for antihyperglycemic agents up to 1-year follow-up after LVAD implantation.
WHAT ARE THE CLINICAL IMPLICATIONS?
• These findings suggest that diabetic patients may be at higher risk for poor outcomes after LVAD; this information should aid in weighing benefits and risks regarding the candidacy of diabetic patients for LVAD implantation.
• Short-term glycemic control prior to LVAD support is inadequate to determine risks of mortality and device-related complications among patients with diabetes.
• Further studies are needed to investigate whether long-term glycemic control can improve outcomes during LVAD support and whether the favorable glycemic control seen after LVAD implantation is of clinical importance.
Outcomes
The primary outcome was all-cause mortality while on LVAD support. Secondary outcomes included LVAD-related complications that might have a mechanistically plausible association with DM, including (1) ischemic stroke or transient ischemic attack (TIA); (2) suspected pump thrombosis; (3) composite end point of thromboembolic events, including ischemic stroke, TIA, or pump thrombosis; (4) LVAD driveline or pump infection; (5) composite end point of nonfatal end points, (6) composite end point of all fatal and nonfatal end points. Survival and clinical events information were obtained from subsequent clinic visits and written correspondence from local physicians. Moreover, glycemic control was assessed in patients supported with LVAD by recording HbA1c levels and anti-DM medications both before LVAD and after at least 3 months up to the last possible follow-up after LVAD implantation. Change in DM medication requirements was defined as change in number of daily doses for insulin therapy and as change in number of medications for oral medical therapy.
Definitions
All 
Statistical Analysis
All variables were tested for normal data distribution. Normally distributed data were expressed as means±SD. Nonnormally distributed data were presented as the median with first and third quartiles (Q1, Q3 Mixed models were performed using direct likelihood estimation with fixed effects of treatment, follow-up, and interaction of treatment by follow-up. An unstructured covariance matrix was used to model within-patient error. All significance tests were 2 tailed and conducted at the 5% significance level.
RESULTS
The [38.8, 60 .0] in DM and non-DM patients, respectively, P=0.33). However, patients with DM were more likely to have ischemic cardiomyopathy (55.7% versus 39.5% in non-DM; P=0.004), increased body mass index (30.6±5.6 versus 28.1±5.5; P<0.001), and higher rates of LVAD implantation as DT (70.2% versus 59.1%; P=0.036) compared with the non-DM group. Among the DM group, 70 patients (53%) were on insulin at baseline whereas 52 patients (40%) were on oral anti-DM agents. Baseline characteristics of the overall cohort and of the study groups (DM and non-DM) are listed in Table 1 .
Effects of DM on Outcomes After LVAD Implantation
The median (Q1, Q3) length of support was 12. Table 2 ). Similarly, the incidence of stroke/TIA was not significantly higher in DM than non-DM patients (9.9% versus 9.5%), and DM status was not associated with stroke/TIA events (unadjusted HR, 1.59; 95% CI: 0.76-3.22; P=0.21). However, DM was significantly associated with the composite end point of thromboembolic events consisting of stroke/ TIA and pump thrombosis (unadjusted HR, 1.61; 95% CI: 1.04-2.45; P=0.03; Table 2 ). Driveline and pump infections were more frequently encountered in the DM group (16.8% versus 14.3%), and DM was associated with significantly higher risk of device infection (unadjusted HR, 2.38; 95% CI: 1.29-4.25; P=0.006; Table 2 ). In addition, DM was associated with higher risk of composite nonfatal (unadjusted HR, 1.74; 95% CI: 1.19-2.52; P=0.004; Figure 2A ), as well as composite fatal and nonfatal events (HR, 1.92; 95% CI: 1.44-2.55; P<0.0001; Figure 2B ).
We constructed proportional hazards (Cox) models after adjustment for the most clinically relevant covariates as described in methods and found that DM remained associated with significantly increased risk of all-cause mortality (adjusted HR, 1.73; 95% CI: 1.18-2.53; P=0.005; 2.0; 95% CI: 1.37-2.86; P=0.0003), and there was a trend toward increased risk of thromboembolic events (HR, 1.6; 95% CI: 0.92-2.82; P=0.096).
Among patients with DM, there was no significant association between all-cause mortality, infection, or thromboembolic events and preoperative HbA1c or postoperative HbA1c (P=NS for all comparisons). Preoperative glycemic control was represented by the last HbA1c available (median [Q1, Q3] of 9 [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] days) before LVAD implantation. About 46% of our patients with DM had pre-LVAD HbA1c ≥7.0 mg/dL. Segregation of patients with DM into 2 groups based on preoperative HbA1c (above and below 7%) did not show significant association of pre-LVAD glycemic control and all-cause mortality (adjusted HR, 1.5 for DM patients with HbA1c ≥7.0 mg/dL; 95% CI: 0.82-2.7; P=0.37; Figure 3 ), neither have we found association with outcomes in a smaller group of 34 patients (26%) with poor DM control (HbA1c ≥8.0 mg/dL). In regard of the effect of insulin therapy on outcomes, there were 70 patients (53.4%) who were on insulin therapy before LVAD. Insulin therapy was associated with no difference in all-cause mortality (HR, 1.14; 95% CI: 0. 
Impact of LVAD Implantation on Glycemic Control
We identified 295 patients who were supported with LVAD for at least 3 months, including 110 patients with DM. We assessed DM control based on HbA1c levels, as well as insulin and oral DM medication requirements after LVAD implantation. Serial HbA1c measurements were collected postoperatively at a median 113 days (n=91) and 361 days (n=59) post-LVAD implantation. Mean HbA1c (±SD) at baseline was 7.4±1.9 mg/dL and was significantly decreased to 6.0±1.5 mg/dL (P<0.001) and 6.3±1.4 mg/dL (P<0.001) at the first and second follow-up measurements, respectively. The distribution of HbA1c values among patients with DM before and at the first and second follow-up measurements after LVAD implantation is presented in Figure 4A . Before LVAD implantation, 27.5% of patients with DM had HbA1c <6.5% compared with 73.3% at 4-month and 64.4% at 12-month follow-up after LVAD. DM control (based on the American Diabetes Association threshold of HbA1c <7%) was achieved in 53.9% of patients before LVAD as compared with 81.2% at 4-month and 72.8% at 12-month follow-up post-LVAD. Compared with baselines, there was a 17.3% decrease and 12.5% decrease in HbA1c levels after 4-and 12-month followup post-LVAD, respectively (P<0.0001 for paired comparisons; Figure 4B ).
During LVAD support, the majority (61%) of patients with DM had a decrease in DM medication requirements at a median follow-up of 4 months, and 49% had a decrease after a median follow-up of 12 months as compared with baseline pre-LVAD requirements (Figure 5A) . Compared with baseline, less patients were on insulin at the 2 follow-up measurements (P<0.001; Figure 5B) . Moreover, LVAD implantation was associated with higher percentage of patients with DM who did not require oral or insulin therapy (46.9% on diet therapy at 4 months and 37.2% at 12 months after LVAD compared with 23.8% before LVAD). Finally, the total 24-hour insulin dose significantly decreased at follow- All outcomes were adjusted for age, sex, rates of ischemic cardiomyopathy, LVAD as DT, and BMI. For all-cause mortality, creatinine, albumin, total bilirubin, international normalized ratio levels, rates of redo-sternotomy, baseline right ventricular dysfunction, and concomitant surgery were added for the adjusted model. For thromboembolic events (pump thrombosis or stroke/TIA), atrial fibrillation, history of stroke, international normalized ratio levels, and LVAD type were added for the adjusted model. BMI indicates body mass index; CI, confidence interval; DM, diabetes mellitus; DT, destination therapy; HR, hazard ratio; LVAD, left ventricular assist device; and TIA, transient ischemic attack.
DISCUSSION
This study reviewed our 9-year experience in a cohort of 341 patients who underwent CF-LVAD implantation seeking to determine whether patients with DM had worse outcomes after LVAD implantation as compared with those without DM and to examine the impact of LVAD support on glycemic control in patients with DM. The salient findings of our study may be summarized as follows: (1) patients with DM had worse post-LVAD implantation outcomes. Specifically, DM was associated with significantly higher all-cause mortality, as well as higher rates of infection and thromboembolic events after adjustment for other variables, (2) Pre-LVAD HbA1c level was not a significant predictor of outcomes in patients with DM during LVAD support, and (3) Glycemic control as indexed by serial HbA1c measurements and requirements for DM medications significantly decreased post-LVAD implantation.
Our findings are consistent with previous studies of patients who were supported with older pulsatile LVADs showing that DM was associated with worse outcomes. 9, 10 Butler et al 9 have demonstrated that patients with DM were at a higher risk of mortality than patients with non-DM after pulsatile LVAD implantation. In another single-center study, which included 49 patients with DM, Topkara et al 10 demonstrated that survival after pulsatile LVAD implantation in patients with DM was significantly lower compared with those without DM. Our study included patients who were supported with CF-LVADs which has become the dominant technology for patients with stage D HF. However, the impact of DM on outcomes of patients supported with CF-LVADs is less established with recent studies showing inconsistent results. First, Boyle et al 13 have shown that preoperative DM was an independent risk factor for ischemic stroke in an analysis of >900 HeartMate II outpatients. Our findings showed an increased risk of thromboembolic events (a composite of stroke/TIA and pump thrombosis), but the rate of ischemic stroke/
Figure 2. Diabetes and risk of averse clinical events after left ventricular assist device (LVAD) implantation.
Post-LVAD cumulative incidence of (A) composite nonfatal device-related events (stroke or transient ischemic attack, pump thrombosis, and device infections) and (B) composite nonfatal (as described above) and fatal (all-cause mortality), segregated by diabetic and nondiabetic group. n=341; number of events=142; χ 2 =31.7; degree of freedom=12; P value for the whole model=0.0015. Pre-LVAD RV dysfunction was defined as right atrial pressure to pulmonary capillary wedge pressure ratio >0.63 based on right heart catheterization before LVAD. Concomitant surgery was defined as performing tricuspid or aortic valve surgery (replacement or repair) during LVAD implantation. BMI indicates body mass index; CI, confidence interval; DM, diabetes mellitus; DT, destination therapy; HR, hazard ratio; INR, international normalized ratio; LVAD, left ventricular assist device; and RV, right ventricle.
TIA alone was not significantly higher among patients with DM. Second, within the Interagency Registry for Mechanically Assisted Circulatory Support national registry, DM was found to be a significant predictor of poor outcome (composite of death and poor quality of life) during the year after CF-LVAD implantation as DT. 14 More recently, Vest et al 11 have reported outcomes of a cohort of 300 CF-LVADs recipients, with 129 patients with DM (43% of all patients), showing no significant association of DM with mortality or rates of any of the adverse event outcomes tested in this study, including stroke/TIA, pump thrombosis, and device-related infection. One explanation of the differences in outcomes between the later study and our findings is that most of LVAD recipients included in the study by Vest et al 11 were implanted as BTT (62%), suggesting inclusion of a healthier cohort of patients with shorter LVAD support time. Our findings are supported by both in vitro and in vivo studies providing mechanistic explanations why DM is associated with increased risk of thromboembolic events and infection. First, there is a strong body of evidence that DM is associated with increased oxidative stress which, via overproduction of reactive oxygen species and reduced nitric oxide bioavailability, induces endothelial dysfunction and inflammation, leading to vascular injury and thrombosis. 15 Importantly, increased oxidative stress and decreased nitric oxide bioavailability have been shown to be strong predictors of cardiovascular events among DM individuals. 16, 17 Both insulin resistance and hyperglycemia cause dysregulation of factors involved in coagulation and platelet activation, leading to a prothrombotic state. 18 Hyperinsulinemia induces tissue factor expression in monocytes of patients with type 2 DM, resulting in increased procoagulant activity and thrombin formation. 19 Second, DM is associated with increased risk of infection with certain infections, including soft tissue infection that is relevant to the LVAD population, are more common in patients with DM. 20 Different aspects of the immune system are altered in patients with DM, including impairment in polymorphonuclear leukocyte adherence, chemotaxis, and bacterial phagocytosis. 21 Antioxidant systems and enzymes important for oxygen-dependent killing of micro-organisms by neutrophils may also be depressed. 22 Moreover, long-standing DM can adversely affect the inflammatory response to pathogens through activation of adhesion molecules on endothelial cells, and DM is involved in impairment of defense mechanisms against microorganism penetration. 23 These altered immune responses to pathogens can explain the increased susceptibility to infection seen in patients with DM. The involvement of the aforementioned mechanisms in the development of adverse clinical outcomes in LVAD patients with DM is unknown, thus warrants further investigation. However, studies have shown that advanced HF is a risk factor for development of insulin resistance, oxidative stress, and inflammation. [24] [25] [26] Importantly, the severity of oxidative stress and inflammatory markers in patients with advanced HF do not decrease (and some markers may even increase) in the early phase of hemodynamic recovery after LVAD implantation. [27] [28] [29] Consequently, one may propose that the coexistence of DM and LVAD in patients with advanced HF may pose an extremely higher risk of adverse outcome than non-DM LVAD patients or patients with DM without HF.
Despite the significant association between DM status and outcomes, our data are not supportive of significant association of pre-LVAD glycemic control (represented by HbA1c level) with outcomes among patients with DM. These findings are consistent with a previous study showing that poor glycemic control at baseline was not associated with increased mortality during LVAD support. 11 Additional studies conducted among observational cohorts that intensified therapy in elderly and in patients with HF reported an increased risk of mortality and cardiovascular disease events. 8, 30 One explanation for the remarkable impact of DM on outcomes regardless of pre-LVAD HbA1c level is that most of the patients had long-standing DM and some were apparently more tightly followed and controlled just adjacent to LVAD implantation. Indeed, most of our patients were controlled with the majority were presented with HbA1c <7.0% before LVAD. Interestingly, recent studies have shown that transient hyperglycemic A, Change in diabetic medication requirements as compared with baseline requirements before LVAD based on changes in number of oral ordaily doses of insulin therapy. B, Change in type of antidiabetic therapies (insulin, oral only, and diet only) before and after LVAD. Compared with baseline, the majority of patients had a decrease in diabetic medication requirements, less patients required insulin, and more patients were converted to diet-based regimen 4 and 12 mo after LVAD implantation.
states in DM can cause persistent epigenetic changes (such as DNA methylation and histone acetylation) of pro-oxidant and proinflammatory genes, leading to endothelial dysfunction and oxidative vascular injury, despite restoration of normoglycemia and achieving target HbA1c levels. 15, 31 This vascular hyperglycemic memory may explain the lack of correlation of HbA1c levels before LVAD implantation with outcomes in this study, as well as the lack of improvement in cardiovascular outcomes with intensive glycemic control seen unanimously in large clinical trials. 32, 33 The dramatic and fast decline in HbA1c seen in the majority of patients with DM after LVAD implantation might be attributed to an increased deformation and turnover of red blood cells, as well as possible changes in glycosylation kinetics, as these cells pass through the LVAD pump more than because of a real favorable glycemic control. Moreover, these patients are frequently transfused normal HbA1c-containing red blood cell units in the setting of LVAD-associated bleeding complications. These challenges suggest that HbA1c might not be a reliable measure and can possibly overestimate a favorable glycemic control in DM patients with LVAD. Interestingly, alternative biomarkers, such as glycated albumin and fructosamine, have been shown to be more reliable than HbA1c for assessing glycemic control in patients with DM who have increased red blood cell turnover states. [34] [35] [36] Further studies are needed to investigate the advantages of these novel biomarkers over HbA1c in assessing glycemic control in patients with DM supported with LVAD.
Despite the questionable role of HbA1c in assessing DM control during LVAD support, other indicators, however, suggest a better DM control after LVAD implantation. This is mainly reflected by the significant reduction in requirements for insulin and for oral medications, indicating an improvement in insulin resistance. Our findings are consistent with previous studies on a small number of patients with DM demonstrating lower insulin requirements with LVAD support. 37, 38 The mechanisms underlying the favorable effects of LVAD on insulin resistance are still unclear. Studies have shown that beyond the increased survival after LVAD implantation, there is a significant improvement in functional capacity and exercise tolerance. 39 Exercise improves metabolic control both via increasing muscle glucose uptake during muscle contractions by insulin-independent mechanisms and by increasing skeletal muscle insulin sensitivity after physical activity. 40, 41 Importantly, exercise also increases skeletal muscle sensitivity and improves glycemic control in people with type 2 DM. 42 Therefore, the increased functional capacity and exercise tolerance in patients with DM after LVAD implantation may explain, at least partially, the favorable effect of LVAD support on glycemic control. In addition, congestive HF has been identified as a risk factor for development and worsening in insulin resistance. 24 Several mechanisms have been proposed for HF-induced insulin resistance and poor glycemic control, including reduced cardiac output resulting in impaired organ perfusion, abnormal sympathetic activation, reduced physical activity, impaired oxidative metabolism, and increased secretion of circulating catecholamines and inflammatory mediators that augment insulin resistance. 25, 26, 43 Because LVAD improves cardiac output and tissue perfusion, it can potentially reverse some of these deleterious metabolic effects in patients with HF and improve glycemic control.
Study Limitations
Our study is limited by its retrospective design. As such, several covariates of interest, particularly for patients with DM , including differentiation between type 1 and type 2 DM, duration of DM, and data on microvascular and macrovascular complications associated with DM (for assessment of DM-related endorgan damage) were not adequately available for analysis. Moreover, data on older HbA1c values (for better assessment of long-term DM control) were also missing, thus the lack of association between HbA1c and outcomes might be attributed to overestimation of good glycemic control only shortly before LVAD implantation rather than a real lack of effect. Additional limitation of this study is that it represents the experience of one single center, where the majority of patients were implanted HeartMate II LVAD as DT, thus results might not be generalized to other health systems with different patients characteristics and using different CF-LVADs. However, despite these limitations, these data have several strengths. The large sample size of this study population and the higher percentage of patients implanted an LVAD as DT allow to identify significant association of DM with adverse outcomes, including all-cause mortality. Finally, although this study was not prospectively designed to test association between DM status and outcomes in LVAD patients, our observational study highlights an impact of DM on outcomes seen in previous large clinical trials, as well as in the real-world practice.
Conclusions
Patients with DM have worse outcomes, including higher rates of death and adverse major events, while on LVAD support. However, glycemic control improved during LVAD support. This study calls for the need of careful consideration when LVAD support for patients with DM is proposed, particularly for those patients with DM with multiple comorbidities. Future prospective studies are warranted to examine the impact of the favorable DM control seen after LVAD implantation on clinical outcomes.
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